AIM ImmunoTech Issues 7.52M Shares at $3.25 Each
AIM ImmunoTech announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7.52M shares of common stock at a purchase price of 3.25c per share. The gross proceeds to the company from the offering are expected to be approximately $2.4M, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the company will issue and sell unregistered Series I warrants to purchase up to 15.04M shares of common stock. The offering is expected to close on or about May 21, subject to the satisfaction of customary closing conditions. Ladenburg Thalmann & Co. is acting as the exclusive placement agent for the offering.
